This study evaluated the mechanism and efficacy of hC2, an anti-γc antibody, versus the JAK3 inhibitor ritlecitinib in alopecia areata (AA), using an ex-vivo human T cell platform and a xenogeneic (human T cell–engrafted) AA-like mouse model.
hC2 restored hair follicle homeostasis and suppressed hair loss by inhibiting autoreactive T cells and tissue-resident memory T cell proliferation, with no significant safety signals; ritlecitinib achieved T cell depletion in vitro but was associated with severe side effects in the mouse model.
Findings are from a humanized murine xenograft model, which may not fully replicate human AA biology; ritlecitinib side-effect data come from the animal model rather than human trials; hC2 is preclinical with no human safety or efficacy data yet.
hC2, a selective γc pathway blocker, may offer a safer alternative to JAK inhibitors for AA by sparing off-target TEC kinase pathways — but clinical validation in humans is still needed before any practice change.
Explore related topics
